• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, March 7

Natco Pharma Ltd has announced the launch of its brand Lymfuda 10 mg tablets.

In a release here on Tuesday, the company said Lymfuda (Fludarabine) is an alkylating agent useful in the treatment of chronic lymphocytic leukaemia (CLL).

CLL is characterised by a large number of cancerous mature lymphocytic and enlarged lymph nodes.

According to the company, there are approximately four patients per every lakh of population suffering from CLL.

Lymfuda is useful when patients are not responding to traditional treatment. Launched for the first time in India, Lymfuda would substitute imports and is competitively priced at around 60 per cent of the cost of the imported medicine, the company claimed.

With this launch, and with the expected revenues from this product, the company expects to become a top player in the oncology segment in the country in terms of revenues, the release said.

More Stories on : Announcements | New Products & Services | Pharmaceuticals | Health

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Monsanto offers to cut trait value of Bt cotton

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line